Jaeck Daniel, Bachellier Philippe, Weber Jean-Christophe, Oussoultzoglou Elie, Greget Michel
Centre de Chirurgie Viscérale et de Transplantation, Hôpital de Hautepierre, Avenue Molière-67098 Strasbourg, France.
Bull Acad Natl Med. 2003;187(5):863-76; discussion 876-9.
Liver resection is the only curative option offering long-term survival in patients with colorectal liver metastases (25 to 40% five-year survival). It can be achieved with low mortality and low morbidity. However, this surgical approach can be offered only for approximately 10 to 20% of patients with colorectal liver metastases. Therefore, 80 to 90% of patients are excluded from liver surgery and will receive palliative therapies. Recent advances have selected subgroups of patients presenting initially unresectable disease to achieve curative resection. These new multidisciplinary strategies were developed in order to increase safely the resecability in patients with initially non-resectable liver metastases and to improve treatment of recurrences in patients with isolated liver metastases either by repeat hepatectomies or local tumor destruction. These strategies offer the same survival than observed in patients with initially resectable liver metastases. Our series includes 438 patients operated on for colorectal liver metastases between 1987 and 2002. Overall mortality was 1.1%, morbidity was 26%. Actuarial 5-year and 10-year survival were respectively 29.6% and 20.1%.
肝切除术是结直肠癌肝转移患者实现长期生存的唯一治愈性选择(五年生存率为25%至40%)。该手术可在低死亡率和低发病率的情况下完成。然而,这种手术方式仅适用于约10%至20%的结直肠癌肝转移患者。因此,80%至90%的患者被排除在肝手术之外,将接受姑息治疗。最近的进展筛选出了最初无法切除的疾病患者亚组,以实现根治性切除。制定这些新的多学科策略是为了安全地提高最初不可切除肝转移患者的可切除性,并通过重复肝切除术或局部肿瘤破坏来改善孤立性肝转移患者复发的治疗。这些策略提供的生存率与最初可切除肝转移患者所观察到的相同。我们的系列研究包括1987年至2002年间因结直肠癌肝转移接受手术的438例患者。总死亡率为1.1%,发病率为26%。精算5年和10年生存率分别为29.6%和20.1%。